The introduction of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable excitement within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to offer impressive improvements in body loss compared to existing therapies. Preliminary clinical data have shown marked decreases in body mass , potentially